|
May 14
|
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
|
|
May 14
|
Altimmune to Participate at Two Upcoming Investor Conferences
|
|
May 13
|
Altimmune Announces First Quarter 2025 Financial Results and Business Update
|
|
May 13
|
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
|
|
May 8
|
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
|
|
May 6
|
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
|
|
Oct 1
|
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
|
|
Sep 30
|
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
|
Jul 25
|
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
|
|
Jun 18
|
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
|
|
Apr 25
|
Altimmune Statement on the Passing of Dr. Stephen Harrison
|
|
Jan 2
|
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
|
|
Nov 30
|
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
|